Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Cost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

BioScience Health Innovations (BHIC) Cost of Revenue (2023 - 2026)

BioScience Health Innovations has reported Cost of Revenue over the past 4 years, most recently at $265350.0 for Q1 2026.

  • Quarterly Cost of Revenue fell 19.82% to $265350.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.4 million through Mar 2026, up 189.07% year-over-year, with the annual reading at $2.4 million for FY2025, 356.65% up from the prior year.
  • Cost of Revenue was $265350.0 for Q1 2026 at BioScience Health Innovations, down from $1.0 million in the prior quarter.
  • Over five years, Cost of Revenue peaked at $1.0 million in Q4 2025 and troughed at $4746.0 in Q1 2023.
  • The 4-year median for Cost of Revenue is $148233.0 (2024), against an average of $258662.8.
  • Year-over-year, Cost of Revenue skyrocketed 825.53% in 2025 and then decreased 19.82% in 2026.
  • A 4-year view of Cost of Revenue shows it stood at $67117.0 in 2023, then surged by 304.09% to $271213.0 in 2024, then surged by 269.04% to $1.0 million in 2025, then crashed by 73.49% to $265350.0 in 2026.
  • Per Business Quant, the three most recent readings for BHIC's Cost of Revenue are $265350.0 (Q1 2026), $1.0 million (Q4 2025), and $433196.0 (Q3 2025).